A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

April 18, 2024

Study Completion Date

August 4, 2024

Conditions
Hyperkalemia
Interventions
DRUG

WS016 3g

Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.

DRUG

WS016 6g

Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.

DRUG

WS016 12g

Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.

DRUG

Matching Placebo

Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.

Trial Locations (26)

100000

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Peking University Shougang Hospital, Beijing

110000

RECRUITING

Shenyang Central Hospital, affiliated to Shenyang Medical College, Shenyang

161000

RECRUITING

The First Hospital of Qiqihar, Qiqihar

200000

RECRUITING

Minhang District Central Hospital, Shanghai

RECRUITING

Shanghai First People's Hospital, Shanghai

RECRUITING

Shanghai No.5 Hospital, Shanghai

RECRUITING

Shanghai Tongji Hospital, Shanghai

210000

RECRUITING

Sir Run Run Hospital, Nanjing Medical University, Nanjing

RECRUITING

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

226000

RECRUITING

The Affiliated Hospital of Nantong University, Nantong

266000

RECRUITING

Qilu Hospital of Shandong University (Qingdao), Qingdao

276100

RECRUITING

The First People's Hospital of Tancheng County, Linyi

300000

RECRUITING

The Second Affiliated Hospital of Tianjin Medical University, Tianjin

RECRUITING

Tianjin People's Hospital, Tianjin

361000

RECRUITING

Zhongshan Hospital, Xiamen University, Xiamen

412000

RECRUITING

Zhuzhou Central Hospital, Zhuzhou

430000

RECRUITING

Wuhan No.4 Hospital, Wuhan

442000

RECRUITING

Shiyan Taihe Hospital, Shiyan

457000

RECRUITING

Puyang Oilfield General Hospital, Puyang

473000

RECRUITING

The First People's Hospital of Nanyang City, Nanyang

750000

RECRUITING

General Hospital of Ningxia Medical University, Yinchuan

071000

RECRUITING

The Affiliated Hospital of Hebei University, Baoding

050000

RECRUITING

Hebei Traditional Chinese Medicine Hospital, Shijiazhuang

RECRUITING

The Second Hospital of Hebei Medical University, Shijiazhuang

010000

RECRUITING

Affiliated Hospital of Inner Mongolia Medical University, Hohhot

All Listed Sponsors
lead

Waterstone Pharmaceutical (Wuhan) Co., LTD.

INDUSTRY

NCT06277128 - A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. | Biotech Hunter | Biotech Hunter